$44.12 Million in Sales Expected for Insmed Incorporated (NASDAQ:INSM) This Quarter

Brokerages expect that Insmed Incorporated (NASDAQ:INSM) will announce sales of $44.12 million for the current quarter, Zacks reports. Three analysts have issued estimates for Insmed’s earnings, with estimates ranging from $42.50 million to $45.15 million. Insmed posted sales of $9.84 million during the same quarter last year, which would indicate a positive year over year growth rate of 348.4%. The company is scheduled to report its next earnings report on Friday, February 28th.

On average, analysts expect that Insmed will report full year sales of $135.09 million for the current financial year, with estimates ranging from $133.30 million to $135.91 million. For the next fiscal year, analysts expect that the business will report sales of $203.73 million, with estimates ranging from $152.30 million to $221.88 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that follow Insmed.

Insmed (NASDAQ:INSM) last posted its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.01). Insmed had a negative return on equity of 114.68% and a negative net margin of 291.19%. The firm had revenue of $38.89 million during the quarter, compared to the consensus estimate of $35.89 million. During the same quarter last year, the company posted ($1.14) EPS.

Several research analysts have commented on INSM shares. Morgan Stanley set a $37.00 target price on shares of Insmed and gave the stock a “buy” rating in a research report on Friday, November 1st. ValuEngine upgraded shares of Insmed from a “hold” rating to a “buy” rating in a report on Monday, November 25th. Credit Suisse Group reiterated a “buy” rating and issued a $40.00 price objective on shares of Insmed in a report on Tuesday, September 10th. Goldman Sachs Group started coverage on shares of Insmed in a report on Tuesday, September 3rd. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Zacks Investment Research cut shares of Insmed from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $35.88.

NASDAQ INSM traded up $0.03 on Friday, hitting $23.08. The stock had a trading volume of 1,116,149 shares, compared to its average volume of 1,062,296. Insmed has a one year low of $11.31 and a one year high of $33.13. The company has a quick ratio of 6.70, a current ratio of 6.97 and a debt-to-equity ratio of 1.19. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of -5.53 and a beta of 3.04. The company’s 50-day moving average is $19.18 and its two-hundred day moving average is $20.80.

In related news, CAO John Goll sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $20.80, for a total transaction of $520,000.00. Company insiders own 4.95% of the company’s stock.

A number of large investors have recently modified their holdings of INSM. Aperio Group LLC boosted its holdings in Insmed by 21.0% during the second quarter. Aperio Group LLC now owns 11,402 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 1,977 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Insmed by 54.6% during the second quarter. DekaBank Deutsche Girozentrale now owns 51,800 shares of the biopharmaceutical company’s stock worth $1,311,000 after buying an additional 18,300 shares in the last quarter. C WorldWide Group Holding A S boosted its holdings in Insmed by 247.5% during the second quarter. C WorldWide Group Holding A S now owns 393,110 shares of the biopharmaceutical company’s stock worth $10,064,000 after buying an additional 280,000 shares in the last quarter. Swiss National Bank boosted its holdings in Insmed by 9.7% during the second quarter. Swiss National Bank now owns 154,100 shares of the biopharmaceutical company’s stock worth $3,945,000 after buying an additional 13,600 shares in the last quarter. Finally, Hillsdale Investment Management Inc. bought a new stake in Insmed during the second quarter worth approximately $740,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Recommended Story: What are the Benefits of Index Funds?

Get a free copy of the Zacks research report on Insmed (INSM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit